Armata Pharmaceuticals, Inc. (ARMP)

Over the past six months, Armata Pharmaceuticals announced the commissioning of its cGMP phage manufacturing facility and filed a Follow-on Equity Offering for $100 million. The company concluded an End-of-Phase 2 meeting with the FDA and plans to advance AP-SA02 into a Phase 3 study. Armata received FDA Qualified Infectious Disease Product (QIDP) designation and Fast Track Designation for AP-SA02. The company delayed its Q4 and full-year 2025 financial results, later reporting a net loss of $124.3 million. Armata announced its 2026 annual meeting of stockholders and appointed Daniel B. Gilmer to its Board of Directors. The stock price has shown significant volatility, with a 52-week high of $16.34 and a 52-week low of $1.17.

The demand for Armata Pharmaceuticals' products is primarily driven by the prevalence of antibiotic-resistant bacterial infections rather than seasonal patterns. The phage therapy market is experiencing growth due to the rising global prevalence of antimicrobial resistance, with surveys indicating substantial demand and willingness to use phage therapy for appropriate cases.

Armata Pharmaceuticals, Inc. is a late clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant bacterial infections. The company's lead therapeutic candidates include AP-SA02 for complicated Staphylococcus aureus bacteremia, AP-PA02 for Pseudomonas aeruginosa chronic respiratory infections, and AP-PA03 for Pseudomonas aeruginosa pneumonia. Armata also has a research collaboration agreement with Merck Sharp & Dohme Corp.

Armata Pharmaceuticals, Inc. is headquartered in Los Angeles, California, and operates a cGMP phage manufacturing facility there. The company's primary operational and manufacturing base is in the United States, while its development efforts target global antibiotic resistance.

Armata Pharmaceuticals' brand reputation has been positively influenced by clinical trial progress and regulatory milestones. Positive Phase 2a diSArm study results for AP-SA02, FDA Qualified Infectious Disease Product (QIDP) designation, and FDA Fast Track Designation for AP-SA02 have contributed to this. The formal commissioning of its cGMP manufacturing facility and a structural biology publication have also enhanced its scientific credibility. A delay in reporting financial results caused temporary concern, but ongoing positive clinical and regulatory news have maintained a generally positive outlook.

Armata Pharmaceuticals, Inc. has a mixed ownership structure, with approximately 0.20% to 2.44% held by institutional investors, 0.61% by insiders, and around 96.96% by retail investors and public companies. Major institutional owners include Vanguard Group Inc., 683 Capital Management, LLC, and BlackRock, Inc. Innoviva, Inc. is also a significant shareholder, and Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc. Insider sentiment is positive, with $15.1 million in acquisitions over the last year.